Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X4P-001 +/- Axitinib in Advanced Renal Cell Carcinoma
NCT02667886Phase 2Completed
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Apr 2016
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of mavorixafor in clear cell renal cell carcinoma (ccRCC), sponsored by X4 Pharmaceuticals, Inc.. Started Apr 2016; status: completed.
02
Drugs
mavorixafor
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02667886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02667886.